Lineage Cell Therapeutics Gross Profit

The latest gross profit for LCTX is $9.1M as of June 2026. That compares with $11M in the prior-year period — down 14.1% year over year. That is below the Healthcare sector average of $65B. Investors often review this figure alongside Lineage Cell Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, LCTX's gross profit moved from $11M to $9.1M — a 14.1% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Lineage Cell Therapeutics's operating scale or balance-sheet position.

Against Healthcare companies, LCTX currently prints $9.1M for gross profit, while the sector average sits near $65B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Lineage Cell Therapeutics's growth, margins, and balance sheet.

A gross profit figure of $9.1M for LCTX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $65B. Explore the charts below for those layers of context.

After noting LCTX's gross profit ($9.1M), review year-over-year change from $11M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.